{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:38:53Z","timestamp":1790127533514,"version":"4.0.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100007543","name":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9","doi-asserted-by":"publisher","award":["2019S015"],"award-info":[{"award-number":["2019S015"]}],"id":[{"id":"10.13039\/501100007543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-40791-1","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T17:25:45Z","timestamp":1772558745000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["PCSK9 inhibitors patterns of use in France from nationwide repeated cross-sectional and cohort studies"],"prefix":"10.1038","volume":"16","author":[{"given":"Allison","family":"Singier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"B\u00e9nard-Laribi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Jarne-Munoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Pariente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwenaelle","family":"Veyrac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Bezin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"40791_CR1","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1146\/annurev-pharmtox-011613-140025","volume":"54","author":"GD Norata","year":"2014","unstructured":"Norata, G. D., Tibolla, G. & Catapano, A. L. Targeting PCSK9 for hypercholesterolemia. Annu. Rev. Pharmacol. Toxicol. 54, 273\u2013293 (2014).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"40791_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach, F. et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur. Heart J. 41, 111\u2013188 (2020).","journal-title":"Eur. Heart J."},{"key":"40791_CR3","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine, M. S. et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Engl. J. Med. 376, 1713\u20131722 (2017).","journal-title":"N. Engl. J. Med."},{"key":"40791_CR4","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz, G. G. et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N. Engl. J. Med. 379, 2097\u20132107 (2018).","journal-title":"N. Engl. J. Med."},{"key":"40791_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-069116","author":"SU Khan","year":"2022","unstructured":"Khan, S. U. et al. PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: A systematic review and network meta-analysis. BMJ https:\/\/doi.org\/10.1136\/bmj-2021-069116 (2022).","journal-title":"BMJ"},{"key":"40791_CR6","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren, F. L. J. et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J. 42, 3227\u20133337 (2021).","journal-title":"Eur. Heart J."},{"key":"40791_CR7","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000625","author":"SM Grundy","year":"2019","unstructured":"Grundy, S. M. et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation https:\/\/doi.org\/10.1161\/CIR.0000000000000625 (2019).","journal-title":"Circulation"},{"key":"40791_CR8","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1016\/j.jacc.2017.10.001","volume":"70","author":"MA Hlatky","year":"2017","unstructured":"Hlatky, M. A. & Kazi, D. S. PCSK9 inhibitors: Economics and policy. J. Am. Coll. Cardiol. 70, 2677\u20132687 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"40791_CR9","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/clc.22713","volume":"40","author":"SJ Baum","year":"2017","unstructured":"Baum, S. J. et al. PCSK9 inhibitor access barriers\u2014issues and recommendations: Improving the access process for patients, clinicians and payers. Clin. Cardiol. 40, 243\u2013254 (2017).","journal-title":"Clin. Cardiol."},{"key":"40791_CR10","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.therap.2023.01.009","volume":"78","author":"S De Germay","year":"2023","unstructured":"De Germay, S. et al. Performing pharmacoepidemiological studies using the French health insurance data warehouse (SNDS): How to translate guidelines into practice. Therapies 78, 679\u2013689 (2023).","journal-title":"Therapies"},{"key":"40791_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1146\/annurev.clinpsy.121208.131413","volume":"6","author":"DS Nagin","year":"2010","unstructured":"Nagin, D. S. & Odgers, C. L. Group-based trajectory modeling in clinical research. Annu. Rev. Clin. Psychol. 6, 109\u2013138 (2010).","journal-title":"Annu. Rev. Clin. Psychol."},{"key":"40791_CR12","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1177\/0049124106292364","volume":"35","author":"BL Jones","year":"2007","unstructured":"Jones, B. L. & Nagin, D. S. Advances in group-based trajectory modeling and an SAS procedure for estimating them. Sociol. Methods Res. 35, 542\u2013571 (2007).","journal-title":"Sociol. Methods Res."},{"key":"40791_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v078.i02","volume":"78","author":"C Proust-Lima","year":"2017","unstructured":"Proust-Lima, C., Philipps, V. & Liquet, B. Estimation of extended mixed models using latent classes and latent processes: the R package lcmm. J. Stat. Soft. 78, 1\u201356 (2017).","journal-title":"J. Stat. Soft."},{"key":"40791_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3532","author":"SM Langan","year":"2018","unstructured":"Langan, S. M. et al. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ https:\/\/doi.org\/10.1136\/bmj.k3532 (2018).","journal-title":"BMJ"},{"key":"40791_CR15","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1080\/10705511.2016.1247646","volume":"24","author":"R Van De Schoot","year":"2017","unstructured":"Van De Schoot, R., Sijbrandij, M., Winter, S. D., Depaoli, S. & Vermunt, J. K. The GRoLTS-checklist: Guidelines for reporting on latent trajectory studies. Struct. Equ. Model. Multidiscip. J. 24, 451\u2013467 (2017).","journal-title":"Struct. Equ. Model. Multidiscip. J."},{"key":"40791_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/S00392-023-02257-6\/FIGURES\/4","author":"W Koenig","year":"2023","unstructured":"Koenig, W., Lorenz, E. S., Beier, L. & Gouni-Berthold, I. Retrospective real-world analysis of adherence and persistence to lipid-lowering therapy in Germany. Clin. Res. Cardiol. https:\/\/doi.org\/10.1007\/S00392-023-02257-6\/FIGURES\/4 (2023).","journal-title":"Clin. Res. Cardiol."},{"key":"40791_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2021.100880","author":"S Talic","year":"2022","unstructured":"Talic, S. et al. Trends in the utilization of lipid-lowering medications in Australia: An analysis of National Pharmacy Claims Data. Curr. Probl. Cardiol. https:\/\/doi.org\/10.1016\/j.cpcardiol.2021.100880 (2022).","journal-title":"Curr. Probl. Cardiol."},{"key":"40791_CR18","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s40256-023-00576-7","volume":"23","author":"SV Deo","year":"2023","unstructured":"Deo, S. V. et al. Disparities in PCSK9 initiation among US veterans with peripheral arterial disease or cerebrovascular disease. Am. J. Cardiovasc. Drugs 23, 311\u2013321 (2023).","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"40791_CR19","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.029707","volume":"12","author":"C LaFratte","year":"2023","unstructured":"LaFratte, C. et al. Association of PCSK9 inhibitor initiation on statin adherence and discontinuation. J. Am. Heart Assoc. 12, e029707 (2023).","journal-title":"J. Am. Heart Assoc."},{"key":"40791_CR20","doi-asserted-by":"publisher","first-page":"e007237","DOI":"10.1161\/CIRCOUTCOMES.120.007237","volume":"14","author":"DM Blumenthal","year":"2021","unstructured":"Blumenthal, D. M. et al. Predictors of PCSK9 (Proprotein Convertase Subtilisin\/Kexin Type 9) inhibitor prescriptions for secondary prevention of clinical atherosclerotic cardiovascular disease. Circ. Cardiovasc. Qual. Outcomes 14, e007237 (2021).","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"40791_CR21","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40261-019-00877-3","volume":"40","author":"C Piccinni","year":"2020","unstructured":"Piccinni, C. et al. PCSK9 inhibitors\u2019 new users: Analysis of prescription patterns and patients\u2019 characteristics from an Italian real-world study. Clin. Drug Investig. 40, 173\u2013181 (2020).","journal-title":"Clin. Drug Investig."},{"key":"40791_CR22","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1007\/s12325-022-02384-y","volume":"40","author":"J Cosin-Sales","year":"2023","unstructured":"Cosin-Sales, J. et al. Identification of secondary prevention patients eligible for PCSK9 inhibitors therapy according to the routine clinical practice in Spain. Adv. Ther. 40, 2710\u20132724 (2023).","journal-title":"Adv. Ther."},{"key":"40791_CR23","doi-asserted-by":"publisher","first-page":"6390","DOI":"10.3390\/jcm12196390","volume":"12","author":"A Praskilevics","year":"2023","unstructured":"Praskilevics, A., Urtane, I. & Latkovskis, G. National trends in the use of state-reimbursed lipid-lowering medications in Latvia (2012-2021). J. Clin. Med. 12, 6390 (2023).","journal-title":"J. Clin. Med."},{"key":"40791_CR24","doi-asserted-by":"publisher","first-page":"e009988","DOI":"10.1161\/CIRCOUTCOMES.123.009988","volume":"17","author":"DE MacDougall","year":"2024","unstructured":"MacDougall, D. E., Baum, S. J., Ahmed, C. D., McGowan, M. P. & Wilemon, K. A. Trends in patient access to and utilization of prescribed PCSK9 inhibitors in a large US claims database from 2015 to 2021. Circ. Cardiovasc. Qual. Outcomes 17, e009988 (2024).","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"40791_CR25","doi-asserted-by":"publisher","DOI":"10.1080\/00015385.2023.2256182","author":"M Snel","year":"2023","unstructured":"Snel, M. & Descamps, O. S. Long-term safety and effectiveness of alirocumab and evolocumab in familial hypercholesterolemia (FH) in Belgium. Acta Cardiol. https:\/\/doi.org\/10.1080\/00015385.2023.2256182 (2023).","journal-title":"Acta Cardiol."},{"key":"40791_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/S00508-023-02245-W","author":"C Ebenbichler","year":"2023","unstructured":"Ebenbichler, C. et al. Evolocumab effectiveness in the real-world setting: Austrian data from the pan-European observational HEYMANS study. Wien. Klin. Wochenschr. https:\/\/doi.org\/10.1007\/S00508-023-02245-W (2023).","journal-title":"Wien. Klin. Wochenschr."},{"key":"40791_CR27","doi-asserted-by":"publisher","first-page":"e003939","DOI":"10.1161\/CIRCOUTCOMES.117.003939","volume":"11","author":"JA Doshi","year":"2018","unstructured":"Doshi, J. A., Puckett, J. T., Parmacek, M. S. & Rader, D. J. Prior authorization requirements for proprotein convertase subtilisin\/kexin type 9 inhibitors across US private and public payers. Circ Cardiovasc. Qual. Outcomes 11, e003939 (2018).","journal-title":"Circ Cardiovasc. Qual. Outcomes"},{"key":"40791_CR28","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1136\/heartjnl-2021-320556","volume":"108","author":"J Li","year":"2022","unstructured":"Li, J. et al. Safety of proprotein convertase subtilisin\/kexin 9 inhibitors: A systematic review and meta-analysis. Heart 108, 1296\u20131302 (2022).","journal-title":"Heart"},{"key":"40791_CR29","first-page":"62","volume":"40","author":"J Cencetti","year":"2023","unstructured":"Cencetti, J. Muscle-related adverse events associated with PCSK9 inhibitors in a veteran population. Fed. Pract. 40, 62 (2023).","journal-title":"Fed. Pract."},{"key":"40791_CR30","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026550","author":"M Arca","year":"2023","unstructured":"Arca, M. et al. Real-world effectiveness of PCSK9 inhibitors in reducing LDL-C in patients with familial hypercholesterolemia in Italy: A retrospective cohort study based on the AIFA monitoring registries. J. Am. Heart Assoc. https:\/\/doi.org\/10.1161\/JAHA.122.026550 (2023).","journal-title":"J. Am. Heart Assoc."},{"key":"40791_CR31","doi-asserted-by":"publisher","first-page":"14347","DOI":"10.1161\/JAHA.119.014347","volume":"9","author":"JA Rymer","year":"2020","unstructured":"Rymer, J. A. et al. Use of low-density lipoprotein-lowering therapies before and after PCSK9 inhibitor initiation. J. Am. Heart Assoc. 9, 14347 (2020).","journal-title":"J. Am. Heart Assoc."},{"key":"40791_CR32","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.atherosclerosis.2023.01.001","volume":"366","author":"P Gargiulo","year":"2023","unstructured":"Gargiulo, P. et al. Efficacy, safety, adherence and persistence of PCSK9 inhibitors in clinical practice: A single country, multicenter, observational study (AT-TARGET-IT). Atherosclerosis 366, 32\u201339 (2023).","journal-title":"Atherosclerosis"},{"key":"40791_CR33","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1093\/eurjpc\/zwae170","volume":"31","author":"P Gargiulo","year":"2024","unstructured":"Gargiulo, P. et al. Strike early-strike strong lipid-lowering strategy with proprotein convertase subtilisin\/kexin type 9 inhibitors in acute coronary syndrome patients: real-world evidence from the AT-TARGET-IT registry. Eur. J. Prev. Cardiol. 31, 1806\u20131816 (2024).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"40791_CR34","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/fcp.12143","volume":"29","author":"J Bezin","year":"2015","unstructured":"Bezin, J. et al. Choice of ICD-10 codes for the identification of acute coronary syndrome in the French hospitalization database. Fundam. Clin. Pharmacol. 29, 586\u2013591 (2015).","journal-title":"Fundam. Clin. Pharmacol."},{"key":"40791_CR35","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00038-018-1186-3","volume":"64","author":"S Fuentes","year":"2019","unstructured":"Fuentes, S. et al. Identifying diabetes cases in health administrative databases: A validation study based on a large French cohort. Int. J. Public Health 64, 441\u2013450 (2019).","journal-title":"Int. J. Public Health"},{"key":"40791_CR36","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1159\/000438859","volume":"74","author":"M Giroud","year":"2015","unstructured":"Giroud, M. et al. Positive predictive value of French hospitalization discharge codes for stroke and transient ischemic attack. Eur. Neurol. 74, 92\u201399 (2015).","journal-title":"Eur. Neurol."},{"key":"40791_CR37","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12874-022-01622-9","volume":"22","author":"M M\u00e9sidor","year":"2022","unstructured":"M\u00e9sidor, M., Rousseau, M.-C., O\u2019Loughlin, J. & Sylvestre, M.-P. Does group-based trajectory modeling estimate spurious trajectories?. BMC Med. Res. Methodol. 22, 194 (2022).","journal-title":"BMC Med. Res. Methodol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40791-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40791-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40791-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T09:37:20Z","timestamp":1773394640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40791-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["40791"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-40791-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"assertion":[{"value":"30 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8866"}}